Balchem Corporation filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

$BCPC
Major Chemicals
Industrials
Get the next $BCPC alert in real time by email

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 18, 2024

Balchem Corporation
(Exact name of registrant as specified in its charter)

Maryland
1-13648
13-2578432
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

5 Paragon Drive, Montvale, NJ 07645
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (845) 326-5600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, par value $.06-2/3 per share
BCPC
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company       

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.          ☐



Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

In order to rebalance the number of directors serving in each class of the Board of Directors (the “Board”) of Balchem Corporation, a Maryland corporation (the “Company”), so that each of the three classes shall consist, as nearly as possible, of one-third of the total number of directors, in accordance with Article III, Section 2 of the Company’s by-laws, effective as of September 20, 2024, (1) Daniel Knutson resigned from his position as Class 2 director and was immediately elected by the Board as Class 3 director; (2) Joyce Lee resigned from her position as Class 2 director and was immediately elected by the Board as Class 3 director; (3) Monica Vicente resigned as Class 2 director and was immediately elected to the Board as Class 1 director; and (4) Kathleen Fish resigned as Class 1 director and was immediately elected to the Board as Class 2 director.

The above resignations and re-elections were effected solely for the purpose of reclassification, and for all other purposes, the respective directors’ service on the Board is deemed to have continued uninterrupted.

The Board now consists of three Class 1 directors whose term will expire at the annual meeting of shareholders to be held in 2025, two Class 2 directors whose term will expire at the annual meeting of shareholders to be held in 2027, and three Class 3 directors whose term will expire at the annual meeting of shareholders to be held in 2026.

Item 5.03
Amendments to Articles of Incorporation or Bylaws.

On September 18, 2024, the Board adopted a resolution providing that the Company elected to be subject to 3-804(c) of the Maryland General Corporation Law, which provides that all vacancies on the Board may be filled only by the affirmative vote of a majority of the directors remaining in office, even if the remaining directors do not constitute a quorum, and any director elected to fill a vacancy shall serve for the remainder of the full term of the class of directors in which the vacancy occurred and until a successor is elected and qualifies. The Company filed Articles Supplementary reflecting such election with the State Department of Assessments and Taxation of the State of Maryland on September 19, 2024. The summary above is qualified in its entirety by reference to the full text of the Articles Supplementary, which is filed as Exhibit 3.1 to this Current Report on Form 8-K, and is incorporated herein by reference.

Item 9.01
Financial Statements and Exhibits.

(d)  Exhibits

Exhibit Number
Description
Articles Supplementary
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
BALCHEM CORPORATION
 
(Registrant)
   
 
By:
/s/ Hatsuki Miyata
 
 
Hatsuki Miyata
 
Executive Vice President, General Counsel and Secretary
   
Date: September 20, 2024
 



Get the next $BCPC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BCPC

DatePrice TargetRatingAnalyst
3/8/2022$170.00 → $155.00Buy
HC Wainwright & Co.
2/22/2022$175.00Neutral → Buy
Sidoti
1/10/2022$160.00 → $170.00Buy
HC Wainwright & Co.
11/29/2021$175.00Buy → Neutral
Sidoti
8/2/2021$140.00 → $145.00Overweight → Equal-Weight
Stephens & Co.
8/2/2021$145.00 → $160.00Buy
HC Wainwright & Co.
More analyst ratings

$BCPC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Balchem Corporation to Participate in the BNP Paribas Exane 13th Consumer Ingredients Conference on March 11, 2025

    MONTVALE, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the BNP Paribas Exane 13th Consumer Ingredients Conference on March 11, 2025. Ted Harris, Chairman of the Board, Chief Executive Officer, and President, Martin Bengtsson, Chief Financial Officer, and Allison Baurichter, Senior Director Investor Relations will participate at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solu

    $BCPC
    Major Chemicals
    Industrials
  • Balchem Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

    MONTVALE, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2024 fiscal fourth quarter ended December 31, 2024. For the quarter, the Company reported net sales of $240.0 million, net earnings of $33.6 million, adjusted EBITDA(a) of $62.8 million, and free cash flow(a) of $39.8 million. Ted Harris, Chairman, President, and CEO of Balchem said, "The fourth quarter capped off another very strong year for Balchem. We delivered record fourth quarter net sales and adjusted EBITDA, with top and bottom line year over year growth in each of our three segments." Fourth Quarter 2024 Financial Highlights:

    $BCPC
    Major Chemicals
    Industrials
  • Balchem Corporation Announces Quarterly Conference Call for Fourth Quarter and Full Year 2024 Financial Results on February 21, 2025

    MONTVALE, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Friday, February 21, 2025, at 11:00 AM Eastern Time (ET) to review fourth quarter and full year 2024 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Fourth quarter and full year results will be published prior to the market opening on Friday, February 21, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-87

    $BCPC
    Major Chemicals
    Industrials

$BCPC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BCPC
SEC Filings

See more

$BCPC
Leadership Updates

Live Leadership Updates

See more
  • AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

    BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an

    $AZRX
    $BCPC
    $BDSI
    Major Pharmaceuticals
    Health Care
    Major Chemicals
    Industrials

$BCPC
Financials

Live finance-specific insights

See more
  • Balchem Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

    MONTVALE, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2024 fiscal fourth quarter ended December 31, 2024. For the quarter, the Company reported net sales of $240.0 million, net earnings of $33.6 million, adjusted EBITDA(a) of $62.8 million, and free cash flow(a) of $39.8 million. Ted Harris, Chairman, President, and CEO of Balchem said, "The fourth quarter capped off another very strong year for Balchem. We delivered record fourth quarter net sales and adjusted EBITDA, with top and bottom line year over year growth in each of our three segments." Fourth Quarter 2024 Financial Highlights:

    $BCPC
    Major Chemicals
    Industrials
  • Balchem Corporation Announces Quarterly Conference Call for Fourth Quarter and Full Year 2024 Financial Results on February 21, 2025

    MONTVALE, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Friday, February 21, 2025, at 11:00 AM Eastern Time (ET) to review fourth quarter and full year 2024 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Fourth quarter and full year results will be published prior to the market opening on Friday, February 21, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-87

    $BCPC
    Major Chemicals
    Industrials
  • Balchem Corporation Announces Dividend

    MONTVALE, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that on December 9, 2024, its Board of Directors declared a dividend on its shares of common stock equal to $0.87 per share on the Company's issued and outstanding Common Stock, to be payable on January 17, 2025 to stockholders of record at the close of business on December 26, 2024. This dividend represents an 10.1% increase over last year's annual dividend. Ted Harris, Balchem's Chairman, President and CEO, said, "Balchem has a long-standing commitment to an annual dividend and we are pleased to announce the continuation of that commitment. This dividend represents the sixteenth consecuti

    $BCPC
    Major Chemicals
    Industrials

$BCPC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more